SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksForterra Regulatory News (FORT)

Share Price Information for Forterra (FORT)

Share Price is delayed by 15 minutes
Get Live Data
130.20    2.40 (1.88%)
Bid:
130.00
Ask:
130.40
Spread: 0.40 (0.308%)
Market Cap: £268.15m
FORT Live PriceLast checked at - London Stock Exchange

Intraday Forterra Share Chart

Director/PDMR Shareholding

1 Feb 2021 16:48

RNS Number : 6201N
Forterra plc
01 February 2021
 

1st February 2021

Forterra plc

Forterra plc (the "Company")

Director / PDMR Shareholdings

Following the vesting on 1 May 2020 of share options granted to management under the 2017 Performance Share Plan (PSP), the Company was notified on the 29 January 2021 that on the 28 January 2021 the following exercise and sale transactions took place:

Stephen Harrison and Ben Guyatt exercised options granted under the PSP as laid out below selling sufficient shares to cover the appropriate tax and national insurance liabilities.

Name

Status

No. of shares exercised

Sale Date

Number of shares sold

Price

Number of shares retained

Beneficial interest

% of ISC

 

Stephen Harrison

PDMR

177,923

28/01/20

84,407

£2.48

93,516

277,018

< 1%

Ben Guyatt

PDMR

31,136

28/01/20

14,773

£2.48

16,363

51,448

< 1%

The 2017 PSP awards were granted with half of the awards subject to an EPS performance condition and the other half of the awards subject to a TSR performance condition. The EPS performance condition vested at 43.57% of the maximum and the TSR performance condition vested at 90.01%. The Remuneration Committee determined that, in accordance with the rules of the scheme, participants would receive dividend equivalent shares at the rate of 1.102917 additional share for every vesting share. The Remuneration Committee also agreed to waive the 1p per option cost upon exercise.

The shares to be retained by management are to be transferred to management by the Employee Benefit Trust.

The above notification is intended to satisfy the Company's obligations under Article 19 of the Market Abuse Regulations.

Enquiries

Forterra plc:

+44 (0) 1604 707 600

Ashley Thompson (Company Secretary)

FTI Consulting:

+44 (0) 20 3727 1340

Richard Mountain/Nick Hasell

Further information relating to the Company and its group can be found at www.forterraplc.co.uk.

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Stephen Harrison

2.

Reason for the notification

a)

Position/status

PDMR (Chief Executive Officer)

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Forterra plc

b)

LEI

213800O5DD6ATBVJAD23

4.

Details of the transaction(s):

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 1p each

 

GB00BYYW3C20

b)

Nature of the transaction

Acquisition of shares for no consideration pursuant to the exercise of nominal cost options (with the 1p option cost waived by the Company) granted under the PSP scheme on 25 April 2017 and vesting on 1 May 2020

c)

Price(s) and volume(s)

Transaction

Price(s)

Volume(s)

 

£Nil

 

 

£2.48

 

 

£Nil

177,923 options vesting

 

84,407 shares sold to settle tax and NI

 

93,516 shares acquired

 

d)

Aggregated information

 

Transaction

Price(s)

Volume(s)

Total

 Sale

£2.48

84,407

£209,329.36

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Ben Guyatt

2.

Reason for the notification

a)

Position/status

PDMR (Chief Financial Officer)

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Forterra plc

b)

LEI

213800O5DD6ATBVJAD23

4.

Details of the transaction(s):

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 1p each

 

GB00BYYW3C20

b)

Nature of the transaction

Acquisition of shares for no consideration pursuant to the exercise of nominal cost options (with the 1p option cost waived by the Company) granted under the PSP scheme on 25 April 2017 and vesting on 1 May 2020

c)

Price(s) and volume(s)

Transaction

Price(s)

Volume(s)

 

£Nil

 

 

£2.48

 

 

£Nil

31,136 options vesting

 

14,773 shares sold to settle tax and NI

 

16,363 shares acquired

 

d)

Aggregated information

 

Transaction

Price(s)

Volume(s)

Total

 Sale

£2.48

14,773

£36,637.04

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUPUQCPUPGGQG
Date   Source Headline
20th Jan 20267:00 amRNSEmployee Benefit Trust Share Purchase
7th Jan 20269:39 amRNSEmployee Benefit Trust Share Purchase
2nd Dec 20259:22 amRNSEmployee Benefit Trust Share Purchase
24th Nov 20259:03 amRNSHolding(s) in Company
20th Nov 20259:13 amRNSHolding(s) in Company
18th Nov 20255:03 pmRNSEmployee Benefit Trust Share Purchase
11th Nov 20257:00 amRNSTrading Update
4th Nov 20254:34 pmRNSEmployee Benefit Trust Share Purchase
24th Oct 20251:36 pmRNSHolding(s) in Company
23rd Oct 20251:21 pmRNSDirector/PDMR Shareholding
17th Oct 20259:58 amRNSEmployee Benefit Trust Share Purchase
14th Oct 20259:06 amRNSHolding(s) in Company
13th Oct 202510:15 amRNSEmployee Benefit Trust Share Purchase
2nd Oct 20252:54 pmRNSGrant of Options under 2025 SAYE Scheme
11th Aug 20251:15 pmRNSHolding(s) in Company
29th Jul 20257:38 amRNS-RProgressive publishes new research
29th Jul 20257:00 amRNSSix months ended 30 June 2025
23rd Jul 202510:05 amRNSHolding(s) in Company
19th Jun 20257:05 amRNSDirector Declaration
20th May 20251:47 pmRNSAnnual General Meeting 2025 Results
20th May 20257:43 amRNS-RProgressive publishes new research
20th May 20257:00 amRNSAGM Trading Update
13th May 202510:36 amRNSHolding(s) in Company
11th Apr 20259:18 amRNSDirector / PCA Shareholdings
2nd Apr 20252:22 pmRNSDirector/PDMR Shareholding
26th Mar 20255:53 pmRNSAnnual Report & Accounts 2024 & Notice of AGM 2025
25th Mar 20251:47 pmRNSDirector/PDMR Shareholding
20th Mar 20252:44 pmRNSHolding(s) in Company
20th Mar 20257:00 amRNSGrant under Performance Share Plan
20th Mar 20257:00 amRNSGrant under Deferred Annual Bonus Plan
18th Mar 20252:23 pmRNSHolding(s) in Company
12th Mar 20258:14 amRNS-RProgressive publishes new research
12th Mar 20257:00 amRNSFull Year Results
6th Mar 20257:00 amRNSAppointment of Independent Non-Executive Director
27th Feb 20253:35 pmRNSHolding(s) in Company
26th Feb 20252:50 pmRNSHolding(s) in Company
4th Feb 20257:00 amRNSDirectorate Change
23rd Jan 20257:00 amRNSFull Year 2024 Trading Update
6th Jan 20259:23 amRNSHolding(s) in Company
2nd Jan 202511:38 amRNSDirector/PDMR Shareholding
11th Nov 20247:00 amRNSTrading update to the end of the October
4th Nov 202410:24 amRNSHolding(s) in Company
30th Oct 20244:54 pmRNSHolding(s) in Company
28th Oct 202411:51 amRNSHolding(s) in Company
2nd Oct 20245:35 pmRNSGrant of Options under 2024 SAYE Scheme
11th Sep 20247:00 amRNSDirectorate Change
5th Sep 202411:49 amRNSHolding(s) in Company
2nd Sep 20249:59 amRNSHolding(s) in Company
12th Aug 20243:03 pmRNSHolding(s) in Company
30th Jul 20247:00 amRNSSix months ended 30 June 2024

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.